Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 1...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Open Forum Infect Dis
मुख्य लेखकों: Alosaimy, Sara, Jorgensen, Sarah C J, Lagnf, Abdalhamid M, Melvin, Sarah, Mynatt, Ryan P, Carlson, Travis J, Garey, Kevin W, Allen, David, Venugopalan, Veena, Veve, Michael, Athans, Vasilios, Saw, Stephen, Yost, Christine N, Davis, Susan L, Rybak, Michael J
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2020
विषय:
Brief Report
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060146/
https://ncbi.nlm.nih.gov/pubmed/32161775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa051
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन